Building on our previous research, which demonstrated the efficacy of preconditioning CAR-T cells with IL-7/IL-15 to augment their anti-tumor capabilities [20], recent studies have shown promise in combining anti-PD-1 antibodies with CAR-T cell therapy for cancer treatment [21–23]. Here, IL7 is linked to neoplasm.